Sapience Therapeutics
Scarsdale
About Sapience Therapeutics
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer. The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $73.5M
- Funding stage: Early Stage Venture
- Last round: Grant (May 2023)
- Website: sapiencetherapeutics.com
- Phone: 914-607-6931
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sapience-therapeutics-110032 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.